Drug Profile
TAK 003
Alternative Names: DEN1-DEN2-DEN3-DEN4 vaccine - Takeda Pharmaceuticals USA; Dengue vaccine tetravalent - Takeda Pharmaceuticals USA; DENVax™; Needle-free dengue vaccine; QDENGA; Qdenga; TAK-003; TDV - Takeda Pharmaceuticals USA; Tetravalent dengue vaccine - Takeda Pharmaceuticals USALatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Centers for Disease Control and Prevention; Inviragen
- Developer PharmaJet; Takeda Pharmaceuticals USA
- Class Attenuated vaccines; Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dengue
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Dengue in Colombia (SC, Injection)
- 01 Feb 2024 Registered for Dengue (In adolescents, In children, Prevention) in Colombia (SC) before February 2024 (Takeda pipeline; February 2024 )
- 04 Oct 2023 Launched for Dengue (In adolescents, In children, Prevention, In adults) in Indonesia, Brazil, European Union, Norway, Liechtenstein, Iceland (SC)